Will giritinib enter medical insurance in 2024?

Gilteritinib is a drug used to treat certain types of leukemia, primarily acute myeloid leukemia (AML) in adults with FLT3 mutations. FLT3Mutation is a common leukemia-related gene mutation, which can lead to excessive proliferation and survival of leukemia cells, thus aggravating the progression of the disease.

Although giritinib has been launched in China, unfortunately, it has not yet been included in the scope of medical insurance. Therefore, the price in the domestic market is relatively high, as high as more than 20,000 yuan. For more specific prices, please consult your local hospital pharmacy directly. Compared with domestic ones, the price of foreign generic drugs is more affordable, especially the price of generic drugs produced in Laos, which is about two to three thousand yuan, which is far lower than the domestic market price. It is worth noting that the ingredients of these generic drugs are highly consistent with the domestic original drugs.

Giritinib belongs to a class of drugs called tyrosine kinase inhibitors. By inhibiting the activity of FLT3 kinase, it blocks the abnormal signaling pathway caused by this gene mutation, thereby inhibiting the proliferation and survival of leukemia cells. The effect of this drug helps to reduce the damage of leukemia cells to the body, prolong the survival time of patients, and improve the success rate of treatment.

TreatmentFLT3mutatedAML has been a challenge because this type of leukemia often has a poor prognosis and lower cure rates. However, the emergence of giritinib provides a new treatment option for these patients. Clinical trial results show that giritinib shows good efficacy and safety in the treatment of patients with FLT3 mutant AML.

Although giritinib has made significant progress in the treatment ofFLT3mutatedAML, it may still cause some adverse reactions, including nausea, vomiting, fatigue, headache, etc. Therefore, before using giritinib, doctors typically evaluate a patient's overall health and weigh the potential benefits and risks.